Literature DB >> 8892319

Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma.

R Matsushima-Nishiwaki1, Y Shidoji, S Nishiwaki, T Yamada, H Moriwaki, Y Muto.   

Abstract

A polyclonal antibody was raised against a recombinant ligand binding domain construct of the human retinoid X receptor (RXR) alpha. This antibody reacted with an endogenous 54 kDa nuclear protein from human hepatoma-derived HuH7 cells in immunoblot analyses. Immunoblotting of nuclear proteins from human hepatocellular carcinomas (HCCs) and their surrounding tissues revealed the presence of a 44 kDa RXR distinct from the 54 kDa RXR and a dramatic decrease in the relative amounts of 44 kDa RXR to 54 kDa RXR in all HCCs compared with normal tissue. In vitro shift and intracellular conversion from 54 kDa RXR to 44 kDa species were observed with the nuclear extracts of HuH7 cells. Furthermore, transfection of hRXR alpha cDNA into HuH7 cells resulted in the increase of 54 kDa RXR, whereas transfected mouse hepatocytes accumulated 44 kDa RXR. These results strongly indicated that 44 kDa RXR was a physiological proteolytic fragment of 54 kDa RXR and that post-translational metabolism of RXR was impaired in HCC and the HuH7 hepatoma-derived cell line.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892319     DOI: 10.1016/0303-7207(96)03863-4

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  13 in total

1.  Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2.

Authors:  Junichi Kitagawa; Takeshi Hara; Hisashi Tsurumi; Soranobu Ninomiya; Kengo Ogawa; Seiji Adachi; Nobuhiro Kanemura; Senji Kasahara; Masahito Shimizu; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2010-07-31       Impact factor: 4.553

2.  Chemoprevention against hepatocellular carcinoma.

Authors:  Jun-Ichi Okano; Yuki Fujise; Ryo Abe; Ryu Imamoto; Yoshikazu Murawaki
Journal:  Clin J Gastroenterol       Date:  2011-06-04

3.  AEG-1 regulates retinoid X receptor and inhibits retinoid signaling.

Authors:  Jyoti Srivastava; Chadia L Robertson; Devaraja Rajasekaran; Rachel Gredler; Ayesha Siddiq; Luni Emdad; Nitai D Mukhopadhyay; Shobha Ghosh; Phillip B Hylemon; Gregorio Gil; Khalid Shah; Deepak Bhere; Mark A Subler; Jolene J Windle; Paul B Fisher; Devanand Sarkar
Journal:  Cancer Res       Date:  2014-08-15       Impact factor: 12.701

4.  The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis.

Authors:  Siva Kumar Kolluri; Maripat Corr; Sharon Y James; Michele Bernasconi; Desheng Lu; Wen Liu; Howard B Cottam; Lorenzo M Leoni; Dennis A Carson; Xiao-kun Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

Review 5.  Targeting truncated RXRα for cancer therapy.

Authors:  Xiaokun Zhang; Hu Zhou; Ying Su
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-10-21       Impact factor: 3.848

6.  Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells--phosphorylated RXR alpha is a critical target for colon cancer management.

Authors:  Kenji Yamazaki; Masahito Shimizu; Masataka Okuno; Rie Matsushima-Nishiwaki; Nobuhiro Kanemura; Hiroshi Araki; Hisashi Tsurumi; Soichi Kojima; I Bernard Weinstein; Hisataka Moriwaki
Journal:  Gut       Date:  2007-06-29       Impact factor: 23.059

7.  Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis.

Authors:  Masahito Shimizu; Yohei Shirakami; Kenji Imai; Koji Takai; Hisataka Moriwaki
Journal:  J Carcinog       Date:  2012-08-30

8.  Nine susceptibility loci for hepatitis B virus-related hepatocellular carcinoma identified by a pilot two-stage genome-wide association study.

Authors:  Li-Shuai Qu; Fei Jin; Yan-Mei Guo; Tao-Tao Liu; Ru-Yi Xue; Xiao-Wu Huang; Min Xu; Tao-Yang Chen; Zheng-Ping Ni; Xi-Zhong Shen
Journal:  Oncol Lett       Date:  2015-11-23       Impact factor: 2.967

9.  Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRα.

Authors:  Liqun Chen; Alexander E Aleshin; Gulimiran Alitongbieke; Yuqi Zhou; Xindao Zhang; Xiaohong Ye; Mengjie Hu; Gaoang Ren; Ziwen Chen; Yue Ma; Duo Zhang; Shuai Liu; Weiwei Gao; Lijun Cai; Lingjuan Wu; Zhiping Zeng; Fuquan Jiang; Jie Liu; Hu Zhou; Gregory Cadwell; Robert C Liddington; Ying Su; Xiao-Kun Zhang
Journal:  Nat Commun       Date:  2017-07-17       Impact factor: 14.919

Review 10.  Posttranslational Modifications of Lipid-Activated Nuclear Receptors: Focus on Metabolism.

Authors:  Natalia Becares; Matthew C Gage; Inés Pineda-Torra
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.